SEC Form 4 · accession 0001193125-26-290484
Monte Rosa Therapeutics, Inc. · GLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony M. Manning
Director
Period of report
Jun 29, 2026
Accepted (ET)
Jun 30, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001826457
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 29, 2026 | M | 10,000 | $4.16 | A | 10,000 | D | |
| Common Stock | Jun 29, 2026 | S | 10,000 | $23.11 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.16 | Jun 29, 2026 | M | 10,000 | D | — | Jun 12, 2034 | Common Stock | 10,000 | 2,100 | D |
Explanation of responses
- F1The shares underlying this option are fully vested and exercisable.
Remarks
Exhibit 24.2 - Substitute Power of Attorney